Suramin (sodium salt)

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor[1]. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) [2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) [3][4]. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor[5]. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent[6][7][8].

Product Specifications

CAS Number

[129-46-4]

Product Name Alternative

Suramin (hexasodium salt)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Parasite; Phosphatase; Reverse Transcriptase; SARS-CoV; Sirtuin; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Suramin-sodium-salt.html

Purity

99.98

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5

Molecular Formula

C51H34N6Na6O23S6

Molecular Weight

1429.17

Precautions

H302, H315, H319, H335

References & Citations

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

SIRT1; SIRT2; SIRT5

Citation 01

Adv Sci (Weinh) . 2025 Nov 6:e14842.|Br J Pharmacol. 2021 Dec;178 (23) :4646-4662.|Cell Metab. 2024 Sep 5:S1550-4131 (24) 00334-6.|J Agric Food Chem. 2023 Oct 4;71 (39) :14263-14275.|J Biol Chem. 2020 Jul 24;295 (30) :10281-10292. |J Biol Chem. 2021 Oct;297 (4) :101166.|J Hematol Oncol. 2025 Apr 1;18 (1) :38.|J Med Chem. 2024 Aug 8;67 (15) :12760-12783.|J Virol Methods. 2021 Dec:298:114283.|Lipids Health Dis. 2023 Dec 13;22 (1) :222.|Nat Commun. 2024 Aug 27;15 (1) :7369.|Nat Struct Mol Biol. 2021 Mar;28 (3) :319-325.|Phys Rev Appl. 2025 Jun 06.|Research Square Preprint. 2020 Nov.|Behav Brain Res. 2023 Aug 24:452:114548.|Biomicrofluidics. 2019 Nov 21;13 (6) :064117.|Clin Transl Med. 2021 Jun;11 (6) :e485.|Int Immunopharmacol. 2023 Jul:120:110295.|Int Immunopharmacol. 2025 Sep 6:165:115494.|J Bone Miner Metab. 2023 Sep;41 (5) :606-620.|Pharmacol Biochem Behav. 2025 Dec:257:174114.